Financial Data and Key Metrics Changes - For Q4 2025, total company revenue was $3.6 billion, representing a 29% increase year-over-year [25] - Full year 2025 total revenue reached $12.9 billion, reflecting a 28% growth from 2024 [28] - Adjusted EBITDA for Q4 was $184 million, a 41% increase compared to Q4 2024, while full year adjusted EBITDA was $618 million, up 34% year-over-year [29][11] - The adjusted EBITDA margin for the company was 4.8%, a 20 basis point increase from 2024 [11] Business Line Data and Key Metrics Changes - Pharmacy Solutions segment revenue for Q4 was $3.2 billion, achieving 32% year-over-year growth, while full year revenue was $11.4 billion, up 31% [25][28] - Provider Services segment revenue in Q4 was $394 million, representing a 13% increase year-over-year, with home healthcare revenue growing 19% to $217 million [27][20] - In the Pharmacy Solutions segment, infusion and specialty revenue was $2.6 billion, growing 43% year-over-year, while home and community pharmacy revenue declined 1% to $593 million [26] Market Data and Key Metrics Changes - The average daily census in home healthcare grew 15% to almost 35,000 in Q4, driven by strong quality metrics and strategic acquisitions [21] - Specialty and infusion script growth was 30% year-over-year in Q4, with total pharmacy script volume at 10.8 million [17] Company Strategy and Development Direction - The company plans to divest the community living business to streamline operations and focus on core patient populations [6] - The acquisition of Amedisys and LHC Home Health Assets is expected to enhance the company's home health capabilities, contributing approximately $30 million to adjusted EBITDA in 2026 [13][35] - The company aims to build a unique and scaled home and community healthcare platform, emphasizing quality outcomes and operational best practices [10] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future of home health and hospice, anticipating a strong growth trajectory over the next 5 to 10 years [50] - The company expects total revenue growth of approximately 14% year-over-year for 2026, with adjusted EBITDA growth of about 25% [13][34] - Management highlighted the importance of executing sales investments and operational efficiencies to drive volume growth and margin expansion [38][39] Other Important Information - The company achieved a leverage ratio of 2.99 times as of December 31, 2025, down from 4.16 times in 2024, indicating improved financial health [32] - The company is initiating a foundation to support community and patient activities, reflecting its commitment to social responsibility [14] Q&A Session Summary Question: Variability in 2026 Outlook - Management noted consistency in Q1 and emphasized the importance of executing strategies to drive volume growth across businesses [37] Question: LDD Introductions and Landscape - Management confirmed expectations for 16-20 new LDD introductions over the next 12-18 months, with a focus on expanding capabilities [40][41] Question: EBITDA and Margins for Segments - Management indicated broad-based margin expansion is expected due to operational efficiencies and favorable product mix [45][46] Question: Home Health Rate Environment - Management expressed optimism about home health rates, projecting a flat baseline with potential for future increases [50] Question: Specialty Drug Launches and Margins - Management highlighted the multifactorial growth in specialty pharmacy, including brand LDDs and generic conversions, which improve margins [55] Question: Amedisys Asset Margins - Management acknowledged the lower margin profile of the Amedisys assets but expressed confidence in improving margins through integration [61][62] Question: Pharmacy Revenue Guidance Components - Management outlined expected revenue headwinds from IRA impacts and generic conversions but anticipated strong growth across pharmacy businesses [70][71] Question: Infusion Business Update - Management reported double-digit growth in the infusion business and plans for significant investments to enhance capabilities [73][75]

Financial Data and Key Metrics Changes - For Q4 2025, total company revenue was $3.6 billion, representing a 29% increase year-over-year [25] - Full year 2025 total revenue reached $12.9 billion, reflecting a 28% growth compared to 2024 [28] - Adjusted EBITDA for Q4 was $184 million, up 41% from the previous year, while full year adjusted EBITDA was $618 million, a 34% increase [29] - The adjusted EBITDA margin for the company was 4.8%, a 20 basis point increase from 2024 [11] Business Line Data and Key Metrics Changes - Pharmacy Solutions segment revenue in Q4 was $3.2 billion, achieving 32% year-over-year growth [25] - Provider Services segment revenue for Q4 was $394 million, representing a 13% increase compared to the prior year [26] - Home Health care revenue grew 19% year-over-year to $217 million in Q4 [27] - Rehab revenue increased by 8% year-over-year, while personal care revenue grew 4% [27] Market Data and Key Metrics Changes - Home health care represented approximately 55% of revenue in the Provider Services segment, with an average daily census growth of 15% [21] - Specialty and infusion script growth was 30% year-over-year in Q4, with total pharmacy script volume at 10.8 million [17] - The company expects to see continued growth in home health, hospice, and infusion markets over the next five to ten years [50] Company Strategy and Development Direction - The company plans to divest the community living business to streamline operations and focus on core patient populations [6] - The acquisition of Amedisys and LHC Home Health Assets is expected to enhance the company's home health capabilities [7] - BrightSpring aims to build a unique and scaled home and community healthcare platform that demonstrates leading quality outcomes [10] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future of home health and hospice, citing a strong runway for growth [50] - The company anticipates total revenue growth of approximately 14% year-over-year for 2026, with adjusted EBITDA expected to grow by about 25% [13] - Management highlighted the importance of executing sales investments and operational efficiencies to drive volume growth [38] Other Important Information - The company achieved a leverage ratio of 2.99x as of December 31, 2025, down from 4.16x the previous year [32] - The expected net cash proceeds from the community living sale are approximately $715 million, which will primarily be used for debt paydown [33] Q&A Session Summary Question: Variability in 2026 Outlook - Management noted consistency in Q1 and emphasized the importance of executing strategies to drive volume growth across businesses [37][38] Question: LDD Introductions and Landscape - Management confirmed expectations for 16-20 new LDD introductions over the next 12-18 months, with a focus on quality and service [40][41] Question: EBITDA and Margins by Segment - Management indicated broad-based margin expansion is expected due to operational efficiencies and favorable product mix [45][46] Question: Home Health Rate Environment - Management remains optimistic about home health rates, projecting a flat baseline with potential for future increases [50] Question: Specialty Drug Launches and Margins - Management highlighted the multifactorial growth in specialty pharmacy, including brand LDDs and generic conversions, which improve margins [56] Question: Amedisys Asset Margins - Management acknowledged the lower margin profile of the Amedisys assets but expressed confidence in improving margins through integration [61][62] Question: Pharmacy Revenue Guidance Components - Management outlined expected revenue headwinds from IRA impacts and brand-to-generic conversions, but still anticipates strong growth across pharmacy businesses [70][71] Question: Infusion Business Update - Management reported double-digit growth in the infusion business and plans for significant expansion in specialty hubs [73][75]

Financial Data and Key Metrics Changes - For Q3 2025, total company revenue was $3.3 billion, representing a 28% increase year over year, with adjusted EBITDA growing approximately 37% to $160 million [9][24][27] - EBITDA margin improved to 4.8%, up 30 basis points compared to the previous year [9][26] - Cash flow from operations exceeded $100 million, and leverage ratio declined to 3.3 times, with a target of 3 times by year-end [10][27] Business Line Data and Key Metrics Changes - Pharmacy Solutions revenue was $3.0 billion, a 31% increase year over year, while Provider Services revenue was $367 million, growing 9% [9][24] - Within Pharmacy Solutions, infusion and specialty revenue reached $2.4 billion, up 42% year over year, while home and community pharmacy revenue was approximately flat at $590 million [24][26] - Provider Services segment adjusted EBITDA grew 16% to $61 million, with home healthcare revenue increasing 12% [18][24] Market Data and Key Metrics Changes - Home healthcare average daily census increased by 3% year over year, with hospice revenue growing approximately 15% [18][19] - Specialty pharmacy scripts grew approximately 40% in Q3, driven by strong performance in both brand limited distribution drugs (LDDs) and generics [15][16] - Home and community pharmacy demonstrated 99.5% order completeness and on-time delivery of 97.2% [12] Company Strategy and Development Direction - The company is focused on quality and continuous improvement, aiming to deliver low-cost, patient-centric care [11][22] - Plans to close the community living divestiture transaction in Q1 2026, which is expected to enhance operational focus [8][29] - The company is optimistic about expanding its presence in targeted markets and enhancing operational efficiency through automation and AI initiatives [84][93] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ongoing growth trajectory, with expectations for continued strong performance in Q4 2025 [10][29] - The company anticipates a positive impact from recent investments in home health, hospice, and rehab services [25][84] - Management remains focused on maintaining high-quality service levels and patient satisfaction across all service lines [11][12] Other Important Information - The company plans to host an Investor Day on March 17 in Louisville to discuss strategy and service line prospects [21] - The adjusted EPS for Q3 was $0.30, reflecting strong operational performance [25] Q&A Session Summary Question: On the pacing of new drug launches - Management confirmed that the pipeline remains robust, expecting 16 to 18 launches over the next 12 to 18 months, with a strong year for brand wins [31][32] Question: On the Amedisys and LHC Home Health Branch acquisitions - Management indicated that the transaction is expected to be accretive in 2026, with integration plans focusing on operational efficiencies [34][36] Question: Sources of accretion from acquisitions - Management highlighted the integration of operations and potential synergies in technology and payer contracts as key sources of incremental margin [40][42] Question: On the sustainability of EBITDA per script growth - Management noted that the increase in EBITDA per script is driven by higher growth in specialty scripts, which have higher gross profit margins [43][45] Question: Impact of community living divestiture delay - Management explained that the delay is due to regulatory processes but remains optimistic for a Q1 closure [68] Question: Future opportunities in specialty pharmacy - Management emphasized ongoing focus on rare and orphan therapies, with expectations for continued growth in the specialty and infusion segments [90][92]

Financial Data and Key Metrics Changes - BrightSpring Health Services reported total revenue of $3.3 billion for Q3 2025, representing a 28% increase year over year [6][21] - Adjusted EBITDA for the quarter was $160 million, reflecting a 37% growth compared to the same period last year [7][24] - The EBITDA margin improved to 4.8%, up approximately 30 basis points year over year [7][24] - Cash flow from operations exceeded $100 million in Q3, with a leverage ratio of 3.3 times at the end of the quarter [8][25] Business Line Data and Key Metrics Changes - Pharmacy Solutions revenue was $3.0 billion, increasing 31% year over year, while Provider Services revenue was $367 million, growing 9% year over year [7][22] - Within Pharmacy Solutions, infusion and specialty revenue reached $2.4 billion, a 42% increase from the prior year, while home and community pharmacy revenue was approximately flat at $590 million [21][22] - Provider Services segment adjusted EBITDA grew 16% to $61 million, with a margin of 16.5%, up 90 basis points year over year [24][16] Market Data and Key Metrics Changes - Home healthcare revenue grew 12% year over year, with an average daily census of 29,592, representing a 3% increase [16][17] - Hospice services saw a 15% increase in revenue year over year, maintaining a high-quality rating [10][16] - The company reported strong growth in specialty scripts, with a 40% increase in Q3, driven by limited distribution drug launches [12][39] Company Strategy and Development Direction - BrightSpring Health Services aims to enhance its position in home and community healthcare, focusing on quality and operational efficiency [5][19] - The company is pursuing acquisitions, including Amedisys and LHC Home Health Branch, expected to close in Q4 2025, which will be neutral to 2025 results but accretive in 2026 [9][33] - The strategy includes expanding into new geographic markets and enhancing chronic therapy offerings [15][80] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ongoing growth trajectory, with expectations for continued strong performance in Q4 2025 [19][72] - The company anticipates achieving a leverage ratio below 3.0 times by year-end, reflecting improved cash flow and operational efficiency [25][74] - Management highlighted the importance of quality metrics and patient satisfaction, which remain high across service lines [10][19] Other Important Information - The community living divestiture is expected to close in Q1 2026, pending regulatory approvals [6][9] - The company is focused on continuous improvement and operational efficiencies, with a new CTO leading AI initiatives [72][80] Q&A Session Summary Question: On the pacing of new drug launches - Management confirmed that the pipeline remains robust, with expectations for 16 to 18 launches over the next 12 to 18 months [30][31] Question: Sources of accretion for the Amedisys transaction - Management indicated that integration will focus on operational efficiencies and leveraging existing practices [34][36] Question: Accretion impact for 2026 - Management stated that the transaction is expected to be accretive in 2026 [33] Question: Growth drivers for specialty pharmacy - Management highlighted strong growth in specialty scripts and the potential for further growth in the infusion market [78][80] Question: Update on M&A pipeline - Management confirmed focus on small, accretive tuck-in deals, with no imminent large transactions [56][57] Question: Impact of community living divestiture delay - Management noted that the process can take time, but they remain optimistic for a Q1 close [61] Question: Future opportunities in pharmacy solutions - Management emphasized growth in rare and orphan therapies, as well as operational efficiencies through automation [78][80]